Sign in

Private company

Chiesi Farmaceutici S.p.A.

Logo: FDRMRZUSA, Public domain, via Wikimedia Commons3

Italian pharmaceutical company

Chiesi Farmaceutici S.p.A. is an Italian family controlled global pharmaceutical company based in Parma, Emilia-Romagna. Chiesi has 31 affiliates in the world, nearly 7,200 total employees and provides medicines to patients in 100 nations. Chiesi currently has revenues of 3,4 billion euros.2 Wikipedia text CC BY-SA 4.0

Last updated Oct 21, 2026.

Overview

1935Founded1

See how the biggest companies compare on our leaderboards

Chiesi Farmaceutici S.p.A. is an Italian family controlled global pharmaceutical company based in Parma, Emilia-Romagna. Chiesi has 31 affiliates in the world, nearly 7,200 total employees and provides medicines to patients in 100 nations. Chiesi currently has revenues of 3,4 billion euros. According to 2020 official data from the European Patent Office (EPO), Chiesi Group, with 42 patents filed, is confirmed as the first Italian Pharmaceutical Company and third among Italian Companies across all sectors for filing the highest number of patents.2

Corporate structure

Chiesi Farmaceutici S.p.A. sits at the top of its group. 4 entities, 4 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

The story

Established in 1935, Chiesi concentrates primarily on developing respiratory, neonatological and rare disease drugs, along with those for treating muscular and skeletal conditions.

Historical therapeutic solutions are a cortisone preparation indicated for asthma, allergic rhinitis and airway inflammation, launched in 1979, and a surfactant life-saving treatment for premature babies, developed by two researchers at Karolinska Institutet, Tore Curstedt and Bengt Robertson.

In the rare disease area, a treatment for moderate to severe limbal stem cell deficiency (LSCD), developed by the researchers Michele De Luca and Graziella Pellegrini, was the first stem cell therapy to be approved in Europe. As well as developing drugs in-house, Chiesi has a policy of developing drugs in collaboration with pharmaceutical businesses outside Italy.

Chiesi's operations regarding neonatological drugs have come under criticism for patenting drugs that Chiesi has not been instrumental in developing. Because of this behavior, some of Europe's neonatology wards have experienced economic hardships.

The company holds over 4,000 international patents for more than 200 patent families and employs approximately 944 people dedicated to Research and Development activities, including regulatory in the R&D centers in Parma (Italy), France, United Kingdom, Sweden, USA, Canada and China.

2010 was the year in which turnover broke through the Billion Euro barrier, with Chiesi recording sales growth of 16.4% over the figure for 2009. By 2013 turnover had reached €1,236, with increases coming primarily from outside the Italian home market.

Chiesi Farmaceutici closes 2016 on a high with an annual turnover of €1.571 million, an increase of more than +7.0% on the previous year (+9.6% at constant exchange rates), and EBITDA equal to €448 million (a year-on-year increase of over 8.2%). The robust health of the company is reflected by its investment in innovation and development, with R&D expenditure rising by over +12.5% in the 2015–2016 period to reach €370 m in 2019, 19% of total sales. The Group currently has 49 active studies in research and development. In 2020 the Chiesi Group reached and exceeded a turnover of 2 billion Euro.

In 2022, the Group recorded a turnover of €2 billion 749 million, an increase of 13.6% compared to 2021. Gross Operating Profit (EBITDA) grew by 7%.

Read the full text

In 2023, the Group recorded a turnover of €3 billion, an increase of 10% compared to 2022. Gross Operating Profit (EBITDA) grew by 30%

In 2022, Chiesi celebrated the start of construction of the new “Biotech Center of Excellence”, located next to the Group’s current Italian production site in Parma. The new R&D and production hub will be operational in 2024, thanks to an investment of 85 million euros, which will allow Chiesi to consolidate its know-how in the field of biotechnology products. The new Centre will embrace the whole end-to-end supply chain, with the first products expected to enter the market in 2025. In line with Chiesi's commitment as a B Corp, the Centre will be built sustainably and in compliance with LEED criteria.

From Wikipedia’s article on Chiesi Farmaceutici, shared under CC BY-SA 4.0.4

Leadership

Who has led Chiesi Farmaceutici S.p.A., and when. Pick a name to see everywhere that person has worked.

Board members and other officers (1)

Subsidiaries and ownership

Subsidiaries

From Wikidata.1

Timeline

  1. 1935Founded Founded1

Calendar

Drug trials and FDA: coming up

  1. Jun 3, 2027Phase 2 trial readout expected Phase 2 trial of CHF5993 pMDI with HFA-152a, CHF5993 pMDI with HFA-134a and others in Asthma: primary completion expected Jun 3, 2027 (ClinicalTrials.gov NCT07301736).5
  2. Oct 2027Phase 2/3 trial readout expected Phase 2/3 trial of PRX-102 1 mg/kg every 2 weeks and PRX-102 2 mg/kg every 4 weeks in Fabry Disease: primary completion expected Oct 2027 (ClinicalTrials.gov NCT05710692).6

Drug trials and FDA: recently

  1. Apr 13, 2026Phase 3 trial completed Phase 3 trial of pegunigalsidase alfa in Fabry Disease: primary completion Apr 13, 2026, no results posted yet (ClinicalTrials.gov NCT03614234).7
  2. May 6, 2022Phase 3 trial completed Phase 3 trial in Chronic Obstructive Pulmonary Disease: primary completion May 6, 2022, results posted May 12, 2026 (ClinicalTrials.gov NCT03888131).8
  3. Dec 28, 2021Phase 3 trial completed Phase 3 trial of Foster 100/6µg NEXThaler and Foster 100/6µg pMDI in Asthma: primary completion Dec 28, 2021, results posted Aug 10, 2026 (ClinicalTrials.gov NCT03453112).9

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9